3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Lymphoma, Non-Hodgkin
3
Recurrence
2
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Hodgkin Disease
2
Various Advanced Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Gastroesophageal Cancer
1
Fallopian Tube Neoplasms
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Advanced Cancer
1
Interventions
Rituximab
55
Cyclophosphamide
41
Lenalidomide
25
Vincristine
23
Doxorubicin
22
Prednisone
21
Etoposide
16
ibrutinib
12
Gemcitabine
12
fludarabine phosphate
10
fludarabine
10
Peripheral Blood Stem Cell Transplantation
10
Carboplatin
10
Bendamustine Hydrochloride
10
Ifosfamide
9
Filgrastim
8
polatuzumab vedotin
7
obinutuzumab
7
Oxaliplatin
7
Mycophenolic Acid
7
Methotrexate
6
Cyclosporine
6
venetoclax
5
tafasitamab
5
Vorinostat
5
Radiotherapy
5
R-CHOP protocol
5
Prednisolone
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Large B-Cell, Diffuse
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts